(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 annual meeting, Dr. Lorenzo Bianchi discussed the external validation of a nomogram for predicting 68Ga-PSMA PET/CT detection rate in patients with prostate cancer recurrence. PSMA functional imaging has proven to have a significant clinical impact in re-staging prostate cancer patients, however, a non-negligible proportion of exams have false-negative results. Recently, Dr. Bianchi’s group proposed a nomogram to identify patients with positive PSMA PET/C in different clinical settings1: